SeeThruEquity Initiates Research Coverage on Tauriga Sciences with Target Price of $0.10
New York, NY / ACCESSWIRE / August 14, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Tauriga Sciences, Inc. (OTCBB: TAUG).
“Tauriga’s current management team, in place since early 2013, has been very opportunistic in completing deals and has actively built out a portfolio of attractive assets in a very short time period. Tauriga is currently developing two main platforms; a natural wellness business featuring medicinal cannabis and cannabis alternative products, and a proprietary synthetic biology technology utilized for industrial waste and wastewater remediation,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a target price of $0.10 per share.”
Additional investment highlights are as follows:
– Natural wellness capitalizing on growing medicinal marijuana market. Tauriga has been very active in 2014 in building out its natural wellness business, highlighted by the acquisition of Honeywood LLC. Honeywood is a California-based medicinal cannabis firm and the formulator of Doc Green’s topical cannabis cream. Doc Green’s lotion was the first professionally packaged and widely distributed cannabis product on the California market, and has won much acclaim including a first prize award at the 2013 High Times Cannabis Cup for Best Non-Edible Medically Infused Product. Honeywood has also developed Vapura, a medicinal cannabis vapor cartridge that attaches to an electronic cigarette battery and produces an effective and flavorful cannabis vapor. Tauriga plans to launch Vapura in 2H14E.
– Cannabis Complements product line provides synergies. Tauriga’s has also recently launched its “Cannabis Complements” product line. The line consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The initial products Tauriga plans to introduce under the Cannabis Complements line are Satietiva, an appetite suppressant, Indicalm, an anxiolytic supplement for anxiety, ClearNaze, a natural and effective non-drug decongestant with neither stimulant nor drowsiness effects, and Endocannabinoid Omega-3 Support, a premium, potent, pure and palatable fish oil supplement to support the efficient function of the endocannaniboid system. On July 28, 2014, Tauriga announced the launch of Satietiva in Colorado through a marketing partnership with The Mary Jane Group.
– Pilus Energy subsidiary developing revolutionary cleantech platform. Tauriga’s other main business focus is a proprietary technology platform in the nano-robotics space being developed by its wholly-owned subsidiary, Pilus Energy LLC (“Pilus”). Pilus is focused on the conversion of industrial “wastewater” into value (“WTV”). Pilus is converging digester, fermenter, scrubber, and other proven legacy technologies into a single scalable Electrogenic Bioreactor (“EBR”) platform. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current electricity, and produce economically important gases and chemicals. The global WTV market is currently estimated at $10bn and expected to grow to $27bn by the year 2021.
The report is available here: TAUG Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
About Tauriga Sciences, Inc.
Tauriga Sciences, Inc. is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 10, 2014, Tauriga acquired a California based topical cannabis lotion company Honeywood LLC.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.